Hormone receptor and human epidermal growth factor receptor 2 status evaluation on thinprep specimens from breast Carcinoma: Correlation with histologic sections determination

Cancer Cytopathology

Volumn 120, Issue 3, 2012, Pages 196-205

  Pegolo, Enrico ^a   Machin, Piernicola ^a   Riosa, Franca ^a   Bassini, Anna ^b   Deroma, Laura ^c   Di Loreto, Carla ^a  

^a UNIVERSITY OF UDINE   (Italy)

^b S MARIA DEGLI ANGELI HOSPITAL   (Italy)

^c SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Breast carcinoma; Cytology; HER2; Hormone receptors; ThinPrep

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; EMBEDDING; FINE NEEDLE ASPIRATION BIOPSY; FLUORESCENCE IN SITU HYBRIDIZATION; FORMALIN FIXED PARAFFIN EMBEDDED; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIMARY TUMOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; TISSUE FIXATION; TISSUE SECTION; BREAST TUMOR; CANCER INVASION; CANCER STAGING; COHORT ANALYSIS; COMPARATIVE STUDY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HISTOLOGY; LABORATORY DIAGNOSIS; METABOLISM; METHODOLOGY; MIDDLE AGED; NEEDLE BIOPSY; PATHOLOGY; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; BIOPSY, FINE-NEEDLE; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROSPECTIVE STUDIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; SENSITIVITY AND SPECIFICITY; SPECIMEN HANDLING; TISSUE EMBEDDING;

EID: 84865129276     PISSN: None     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.20206     Document Type: Article

References (26)

1. Kontzoglou K, Moulakakis KG, Konofaos P, Kyriazi M, Kyroudes A, Karakitsos P. The role of liquid-based cytology in the investigation of breast lesions using fine-needle aspiration: a cytohistopathological evaluation. J Surg Oncol. 2005;89:75-78.
2. Bishop JW, MacFarlane K, Cheuvront D, Sims KL. Cell recovery and appearance in thin-layer preparations in nongynecologic cytology. Anal Quant Cytol Histol. 1998;20:229-237.
3. Leung CS, Chiu B, Bell V. Comparison of ThinPrep and conventional preparations: nongynecologic cytology evaluation. Diagn Cytopathol. 1997;16:368-371.
4. Hoda RS. Non-gynecologic cytology on liquid-based preparations: a morphologic review of facts and artifacts. Diagn Cytopathol. 2007;35:621-634.
5. Fadda G, Rossi ED, Mule A, Miraglia A, Vecchio FM, Capelli A. Diagnostic efficacy of immunocytochemistry on fine needle aspiration biopsies processed by thin-layer cytology. Acta Cytol. 2006;50:129-135.
6. Veronesi U, Boyle P, Goldhirsch A, Orecchia R, Viale G. Breast cancer. Lancet. 2005;365:1727-1741.
7. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451-1467.
8. Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124:966-978.
9. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
10. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659-1672.
11. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28: 2784-2795.
12. Wolff AC, Hammond ME, Schwartz JN, et al American Society of Clinical Oncology/College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131: 18-43.
13. Idirisinghe PK, Thike AA, Cheok PY, et al. Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical significance. Am J Clin Pathol. 2010;133:416-429.
14. Bédard YC, Pollett AF. Breast fine-needle aspiration. A comparison of ThinPrep and conventional smears. Am J Clin Pathol. 1999; 111:523-527.
15. Tabbara SO, Sidawy MK, Frost AR, et al. The stability of estrogen and progesterone receptor expression on breast carcinoma cells stored as PreservCyt suspensions and as ThinPrep slides. Cancer. 1998;84:355-360.
16. Sauer T, Ebeltoft K, Pedersen MK, Kåresen R. Liquid based material from fine needle aspirates from breast carcinomas offers the possibility of long-Time storage without significant loss of immunoreactivity of estrogen and progesterone receptors. Cytojournal. 2010;7:24.
17. Konofaos P, Kontzoglou K, Georgoulakis J, et al. The role of ThinPrep cytology in the evaluation of estrogen and progesterone receptor content of breast tumors. Surg Oncol. 2006;15:257-266.
18. Leung SW, Bédard YC. Estrogen and progesterone receptor contents in ThinPrep-processed fine-needle aspirates of breast. Am J Clin Pathol. 1999;112:50-56.
19. Nishimura R, Aogi K, Yamamoto T, et al. Usefulness of liquidbased cytology in hormone receptor analysis of breast cancer specimens. Virchows Arch. 2011;458:153-158.
20. Hanley KZ, Birdsong GG, Cohen C, Siddiqui MT. Immunohistochemical detection of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast carcinomas: comparison on cell block, needle-core, and tissue block preparations. Cancer. 2009;117:279-288.
21. Williams SL, Birdsong GG, Cohen C, Siddiqui MT. Immunohistochemical detection of estrogen and progesterone receptor and HER2 expression in breast carcinomas: comparison of cell block and tissue block preparations. Int J Clin Exp Pathol. 2009;2:476-480.
22. Sumiyoshi K, Shibayama Y, Akashi S, et al. Detection of human epidermal growth factor receptor 2 protein and gene in fine needle aspiration cytology specimens and tissue sections from invasive breast cancer: can cytology specimens take the place of tissue sectionsOncol Rep. 2006;15:803-808.
23. Moriki T, Takahashi T, Ueta S, Mitani M, Ichien M. Hormone receptor status and HER2/neu overexpression determined by automated immunostainer on routinely fixed cytologic specimens from breast carcinoma: correlation with histologic sections determinations and diagnostic pitfalls. Diagn Cytopathol. 2004;30:251-256.
24. Kumar SK, Gupta N, Rajwanshi A, Joshi K, Singh G. Immunochemistry for oestrogen receptor, progesterone receptor and HER2 on cell blocks in primary breast carcinoma. Cytopathology. 2011; doi:10.1111/j.1365-2303.2011.00853.x.
25. Bédard YC, Pollett AF, Leung SW, O'Malley FP. Assessment of thin-layer breast aspirates for immunocytochemical evaluation of HER2 status. Acta Cytol. 2003;47:979-984.
26. Beatty BG, Bryant R, Wang W, et al. HER-2/neu detection in fine-needle aspirates of breast cancer: fluorescence in situ hybridization and immunocytochemical analysis. Am J Clin Pathol. 2004; 122:246-255.